AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$NVAX

Novavax’s (NASDAQ:NVAX) Q3 2026: strong sales, guides for strong full-year sales

Novavax (NVAX) reported Q3 2026 revenue of $68.3M, down 3% YoY but 52.4% above estimates. Full-year guidance of $400M is 4.2% above consensus. GAAP loss of $0.19 per share beat estimates by 45.1%. Operating margin improved to -45.8%. Analysts expect revenue to decline 3.9% over the next 12 months, with EPS turning positive.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 2:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Novavax’s (NASDAQ:NVAX) Q3 2026: strong sales, guides for strong full-year sales — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$NVAXBullishMed
01

Why it matters

The earnings beat and raised guidance provide a short‑term upside catalyst, but underlying profitability concerns limit the rally.

02

Market read

First‑report earnings release with a beat and upgraded guidance, offering a medium‑term trading opportunity.

03

What to watch

Long-term demand trends are weak, and operating margins remain deeply negative.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Novavax is a vaccine biotechnology company that has struggled with revenue growth over the past years.

Company-level read

Ticker impact

$NVAXBullishHigh confidence
Context

Novavax reported Q3 2026 revenue of $68.3M beating estimates and raised full-year guidance to $400M, a fresh earnings release.

Expected impact

likely upward pressure as market prices in the beat and raised guidance

Evidence & confidence

The beat was 52.4% over consensus and guidance is 4.2% above estimates, providing a clear catalyst.

Market effects

Sector

Improves sentiment for vaccine biotech sector, may benefit peers with similar pipelines.

Regional

Limited to US-listed biotech investors.

Global

Modest; primarily affects NVAX and related biotech stocks.

Counterpoint

What could challenge this read

Guidance still modest and revenue remains low; investors may remain cautious.

Key entities

  • Company
    Novavax

    Vaccine biotech firm reporting Q3 2026 results.

Read at source← All news

StoryNovavax Raises 2026 Revenue Guidance After Sanofi Vaccine Milestone

Also covered by

4 outlets

Related articles

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

finance.yahoo.com
$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.

finance.yahoo.com
$NVAXHighAI 8/10

Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

Novavax reported a narrower-than-expected Q3 loss of $0.19 per share, beating estimates by $0.18, with revenue of $68.3M, exceeding expectations by $17.7M. The company raised its full-year revenue outlook to $400M, including a $125M milestone from Sanofi. However, profitability is now expected in 2029, pushed back from 2028, due to delayed milestones and reduced recurring revenue.

finviz.com